Opioids

Mason and Partner Clinics see 189% increase in appointments since 2018 and delivered $3.8 million in free services to the community

mthomp7 — Wed, 04 Oct 2023 13:14:41 +0000

Mason and Partner Clinics see 189% increase in appointments since 2018 and delivered $3.8 million in free services to the community mthomp7 Wed, 10/04/2023 - 09:14

Rebcca Sutter discusses the opioid services offered at the MAP Clinics with Representative Jennifer Wexton.

Empowered Communities Opioid Partnership extends Mason’s efforts to reduce overdoses for those involved in the criminal justice system

Rebecca Sutter, professor in the School of Nursing and director of the Mason and Partner Clinics also oversees the Empowered Communities Opioid Partnership (ECOP) – a $2.8 million initiative serving five local health districts (Prince William, Chesterfield, Crater, Portsmouth, and Norfolk) with the goal of reducing opioid-related overdose deaths, non-fatal overdoses, and adverse health consequences among those newly released from jail or prison.

“The chance of overdose or relapsing can be up to 129% higher in the two weeks after release, so we are committed to working with partners in the criminal justice and community-based systems of care to connect high-risk individuals quickly and with low barriers to the care they need,” said Sutter. ECOP has screened more than 950 patients to date and is looking at opening a dedicated Center in early 2024.

In This Story

Rebecca Sutter, DNP, APRN, BC-FNP

Mason and Partner Clinics see 189% increase in appointments since 2018 and delivered $3.8 million in free services to the community

Economic downturn and reductions in Medicaid coverage drive demand for free wellness, preventative, and COVID-related services.

For the past five years, the Mason and Partner (MAP) Clinics have filled an important gap in community health services. In close partnership with area health districts and other service providers, the MAP Clinics have responded to community need with increased accessibility, expanded services, and unwavering support.

During the COVID-19 pandemic alone, the nine MAP Clinics delivered more than 58,220 vaccines and 6,650 COVID tests – providing more than $3,800,000 in free services to the community. The pandemic not only increased demand for health care – it raised awareness about the valuable services offered by the MAP Clinics.

MAP Clinic faculty and staff built deep trust and relationships within the communities they serve – which created a natural place to seek care when economic challenges and/or Medicaid reductions adversely affected vulnerable populations. In addition, the MAP Clinics placed a greater emphasis on preventive care and education post-pandemic to help patients manage their health conditions before they become severe.

“To best meet the needs of the community, the MAP Clinics continually seek new collaborations and partnerships with grassroot community organizations and government agencies. With the deepening opioid crisis, we’ve expanded access for those suffering from this horrible disease through expansion of our Medication for Opioid Use clinics and have expanded our network of peer-recovery support specialists to further assist those struggling with addiction,” says Rebecca Sutter, professor in the School of Nursing and director of the Mason and Partner Clinics.

Topics

MAP Clinic

Mason and Partners Clinic

Study: When Recreational Cannabis Is Legal, Codeine Demand Drops

Andrew J Schappert — Tue, 24 Jan 2023 13:49:46 +0000

Study: When Recreational Cannabis Is Legal, Codeine Demand Drops Andrew J Schappert Tue, 01/24/2023 - 08:49

In This Story

Catherine Maclean

Request program information

Learn more about the Schar School

Catherine Maclean: ‘…[C]annabis use is arguably less harmful to health than the nonmedical use of prescription opioids.’

A new study published this month in Health Economics finds a significant reduction in pharmacy-based codeine distribution in states that have legalized recreational cannabis use. The finding is promising from a public health policy perspective because misuse of prescription opioids contributes to more than 10,000 overdose deaths a year in the U.S.

The study was coauthored by associate professor Johanna Catherine Maclean of the Schar School of Policy and Government at ��AV. The research was supported by the National Institute on Drug Abuse of the National Institutes of Health.

So far, 21 U.S. states have passed recreational cannabis laws; legislatures in other states are considering similar measures.

“A reduction in the misuse of opioids will save lives,” said doctoral candidate Shyam Raman who is affiliated with the Cornell Jeb E. Brooks School of Public Policy and the lead author of the study. “Our research indicates that recreational cannabis laws substantially reduce distribution of codeine to pharmacies, an overlooked potential benefit to legalizing recreational cannabis use.”

Maclean, who specializes in the study of substance use disorder and public policy, said that while cannabis and opioids can be used to minimize chronic pain symptoms, they aren’t equivalent in their impact on overall health.

“Increasing legal access to cannabis may shift some consumers away from opioids and toward cannabis,” she said. “While all substances have some risks, cannabis use is arguably less harmful to health than the nonmedical use of prescription opioids.”

The study is believed to be among the first to separately examine the impact of recreational cannabis laws on shipments of opioids to hospitals, pharmacies, and other endpoint distributors. Previous studies have focused on medical cannabis laws or the use of opioids by subsets of consumers, such as Medicaid beneficiaries.

The researchers analyzed data from the Drug Enforcement Administration’s Automation of Reports and Consolidation Orders System which tracks the flow of controlled substances in the U.S.

Key findings from states that passed recreational cannabis laws:

A 26 percent reduction in pharmacy-based distribution of codeine and as much as a 37 percent reduction after recreational cannabis laws have been in effect for four years.
Minimal impact on distribution of other opioids such as oxycodone, hydrocodone, and morphine in any setting.
Minimal impact on codeine distribution by hospitals, which often have less permissive policies than pharmacies.

“This finding is particularly meaningful,” said senior author Coleman Drake of the University of Pittsburgh’s School of Public Health. “Where previous studies have focused on more potent opioids, codeine is a weaker drug with a higher potential for addiction. It indicates people may be obtaining codeine from pharmacies for misuse, and that recreational cannabis laws reduce this illicit demand.”

“Our study contributes new information to policy debates regarding legalization of recreational cannabis, which is a complex decision,” added Maclean. “Lawmakers could weigh the benefits we document alongside benefits and costs across a range of health, social, and economic domains potentially impacted by cannabis as they determine whether legalization is appropriate for their constituents.”

W. David Bradford of the University of Georgia also contributed to the study.

Additional reporting by Jim Hanchett, assistant dean for communications for the Cornell Jeb E. Brooks School of Public Policy. Cornell’s announcement is here.

Topics

Schar School News January 2023

Research

Partnership harnesses Virginia’s ‘intellectual horsepower’ to fight opioid epidemic

Colleen Rich — Wed, 18 Sep 2019 19:35:39 +0000

Partnership harnesses Virginia’s ‘intellectual horsepower’ to fight opioid epidemic Colleen Rich Wed, 09/18/2019 - 15:35

Topics

Institute for Biohealth Innovation

Opioids

Bill Hazel

Research